ScholarIQanswers from OpenAlex
Palacký University Olomouc
InstitutionResearch output, impact & collaborations
Palacký University Olomouc is a institution indexed in ScholarIQ from OpenAlex.
What is known about Palacký University Olomouc?
ScholarIQrecord summary
Palacký University Olomouc is a research organisation in Olomouc, CZ. OpenAlex records 37,988 works and 2,286,777 citations for it. 6,873 researchers list it as their most recent affiliation.
How many works does Palacký University Olomouc have?
ScholarIQindexed works
Palacký University Olomouc has 37,988 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Palacký University Olomouc have?
ScholarIQcitation count
Palacký University Olomouc has 2,286,777 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Palacký University Olomouc?
ScholarIQresearcher count
Palacký University Olomouc has 6,873 researchers in the ScholarIQ index.
What is the average h-index at Palacký University Olomouc?
ScholarIQavg h-index
Palacký University Olomouc has an average h-index of 84.5 in OpenAlex.
What is the ROR of Palacký University Olomouc?
ScholarIQror
The ROR for Palacký University Olomouc is on the source record.
What is the OpenAlex record for Palacký University Olomouc?
ScholarIQopenalex
The OpenAlex for Palacký University Olomouc is on the source record.
Who are the most-cited researchers behind Palacký University Olomouc?
ScholarIQtop researchers by citations
What are the most-cited papers on Palacký University Olomouc?
ScholarIQmost cited works
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Robert J. Motzer, Nizar M. Tannir, Ray McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Toni K. Choueiri, Elizabeth R. Plimack, Philippe Barthélémy, Camillo Porta, Saby George, Thomas Powles, Frede Donskov, Victoria Neiman, Christian Kollmannsberger, Pamela Salman, Howard Gurney, Robert D. Hawkins, Alain Ravaud, Marc‐Oliver Grimm, Sergio Bracarda, Carlos H. Barrios, Yoshihiko Tomita, Daniel Castellano, Brian I. Rini, Allen C. Chen, Sabeen Mekan, M. Brent McHenry, Megan Wind‐Rotolo, Justin Doan, Padmanee Sharma, Hans J. Hammers, Bernard Escudier
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Charles S. Fuchs, Jiří Tomášek, Cho Jae Yong, Filip Dumitru, Rodolfo Passalacqua, Chanchal Goswami, Howard Safran, Lucas Vieira dos Santos, Giuseppe Aprile, David Ferry, Bohuslav Melichar, Mustapha Tehfé, Э. Э. Топузов, John Zalcberg, Ian Chau, William Campbell, Choondal Devan Sivanandan, Joanna Pikiel, Minori Koshiji, Yanzhi Hsu, Astra M. Liepa, Ling Gao, Jonathan D. Schwartz, Josep Tabernero
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert J. Motzer, B. Yа. Alekseev, Sun Young Rha, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E. Hutson, Evgeny Kopyltsov, María José Méndez-Vidal, Vadim Kozlov, Anna Alyasova, Sung‐Hoo Hong, Anil Kapoor, Teresa Alonso Gordoa, Jaime R. Merchan, Eric Winquist, Pablo Maroto, Jeffrey C. Goh, Miso Kim, Howard Gurney, Vijay Patel, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Bohuslav Melichar, Frédéric Rolland, Ugo De Giorgi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Corina E. Dutcus, Alan D. Smith, Lea Dutta, Kalgi Mody, Rodolfo F. Perini, Dongyuan Xing, Toni K. Choueiri
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
Funda Meric‐Bernstam, Vicky Makker, Ana Oaknin, Do‐Youn Oh, Susana Banerjee, Antonio González-Martı́n, Kyung Hae Jung, Iwona Ługowska, Luís Manso, Aránzazu Manzano, Bohuslav Melichar, Salvatore Siena, Daniil Stroyakovskiy, Anitra Fielding, Yan Ma, Soham D. Puvvada, Norah J. Shire, Jung‐Yun Lee
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
Sun Young Rha, Sun Young Rha, Do-Youn Oh, Patricio Yañez, Yuxian Bai, Min-Hee Ryu, Jeeyun Lee, Fernando Rivera, Gustavo Vasconcelos Alves, Marcelo Garrido, Kai-Keen Shiu, Manuel González Fernández, Jin Li, Maeve A Lowery, Timuçin Çil, Felipe Melo Cruz, Shukui Qin, Suxia Luo, Hongming Pan, Zev A Wainberg, Lina Yin, Sonal Bordia, Pooja Bhagia, Lucjan S Wyrwicz, Guillermo Méndez, Juan Manuel O’Connor, Alvaro Yanzi Castilla, Juan Cundom, Diego Kaen, Rachel Wong, Weng Ng, Morteza Aghmesheh, Mauricio Peressoni, Carlos Eduardo Mattos da Cunha Andrade, Fábio Franke, Gustavo R. Alves, Felipe Jose Cruz, Karina Vianna, Maria Marcela Monteiro, Michael J. Raphael, Scott Berry, Raymond Woo-Jun Jang, Ann Tan, Jamil Asselah, Patricio Yañez Weber, Mauricio Mahave, César Sánchez, Pamela Salman, Yuxian Bai, Jin Li, Xiaochun Zhang, Tianshu Liu, Xiaoyan Lin, Shukui Qin, Jianwei Yang, Suxia Luo, Wěi Li, Jieer Ying, Xi Chen, Shan Zeng, Yanli Qu, Lin Yang, Lin Zhao, Ping Chen, Hongming Pan, Enxiao Li, Feng Ye, Jianwei Lu, Xinjun Liang, Qun Zhao, Xianli Yin, Junhe Li, Ling Yang, Guoqing Lv, Shouguo Li, Álvaro Guerrero, Juan Rubiano, Manuel Gonzalez Fernandez, Ray Manneh Kopp, Adrián Guzmán Ramírez, Luis Corrales, Ileana Gonzalez Herrera, Bohuslav Melichar, Tomáš Büchler, Tomáš Svoboda, Radka Obermannová, David Vrána, Jakub Cvek, Per Pfeiffer, Lene Bæksgaard, Mette Yilmaz, Valérie Boige, Daniel López‐Trabada, Christophe Borg, Diane Pannier, Sandrine Hiret, Frédéric Di Fiore, Jean‐Philippe Metges, Dirk Arnold, Uwe M. Martens
How much of the research on Palacký University Olomouc is open access?
ScholarIQopen access share
82%OPEN ACCESS